MAESTRO: Molecular stratification profiling in mCRPC
Research type
Research Study
Full title
MAESTRO: Molecular stratification profiling protocol in metastatic Castration Resistant Prostate Cancer (mCRPC)
IRAS ID
208950
Contact name
Johann De Bono
Contact email
Sponsor organisation
Institute of Cancer Research
Duration of Study in the UK
5 years, 0 months, 1 days
Research summary
This study is a prospective, observational, molecular stratification profiling study. Patients with mCRPC who have received at least one standard treatment for mCRPC will be approached to participate in MAESTRO. Patients must have archival tumour available and be willing to undergo a fresh tumour biopsy, for molecular analyses. Tumour tissue (archival and fresh), research blood samples and saliva will be sent to the central laboratory for analysis to identify molecular aberrations through targeted or broader molecular analyses (eg exome, transcriptome) and orthogonal assays (eg immunohistochemistry; digital droplet PCR). When the results are available, depending on patients choice, the results will be discussed. If significant results are indicated, patients will be recommended to have follow-up with a cancer geneticist to discuss the implications of these results for their personal and family’s health.
There is a safety follow up 30 days after collection of study biopsy or blood samples. Patients will also be followed up for overall survival and subsequent anticancer treatment every 6 monthly via medical notes or telephone calls.
REC name
London - Surrey Borders Research Ethics Committee
REC reference
19/LO/0293
Date of REC Opinion
15 May 2019
REC opinion
Further Information Favourable Opinion